GLP1R and type 2 diabetes mellitus: The peptide drug exendin-4 (brand name Byetta), derived from the Heloderma suspectum (Gila monster), was introduced in 2005 for the treatment of type 2 diabetes by activating the glucagon-like peptide-1 receptor (GLP-1R).35